OTLC Oncotelic Therapeutics Inc

$OTLC - Bear set the looks bloody here! - Get ready to see the Bulls in chart - Momentum and Accumulation Response

$OTLC Dr Scam back to paying pumpers here and on yahoo. Must be trying to raise more money off poopoo tokens. Mike.gettimg his $5/post is so OBVIOUS!

$OTLC -the pumping steps up - as bid just gets smacked out…. At this point just announce some more junk so i can get out- this one is too obvious- but usually they at least get the stock up… not easy on the otc anymore- so many less participants- 11 cents last year wasn’t nothing-

$OTLC cont’d…financing outlined 3. The Real Funding Vehicle: GMP Bio Joint Venture Because Oncotelic itself lacks the cash runway, the financial weight of the OT-101 Phase 3 trial has been offloaded to its GMP Bio Joint Venture (in which Oncotelic owns a 45% equity stake). • Asset Offloading: The joint venture manages the operational execution and uses its fully operational manufacturing facility in San Diego to support the program. • The Exit Strategy: To properly fund the trial through 2027, the joint venture has been preparing for a potential Initial Public Offering (IPO) on the Hong Kong Stock Exchange.

$OTLC 1. Minimal Standalone Cash Reserves Oncotelic's internal cash levels are dangerously low, carrying virtually zero liquid capital. Standing cash on hand has historically hovered at less than $200,000, which is nowhere near enough to fund multi-year clinical trials. Because standard Phase 3 trial costs millions of dollars annually, Oncotelic cannot rely on its own balance sheet to reach 2027. 2. High Reliance on Hand-to-Mouth Financing To survive month-to-month, the company continuously uses small, highly dilutive funding injections. For example, they recently secured a $178,410 convertible note agreement. • The Mismatch: This note carries a one-year maturity period, forcing the company to pay it back or convert it to stock long before the June 2027 clinical readout. • The Risk: These short-term notes give investors the right to convert debt into common stock at steep discounts. This process creates ongoing shareholder dilution, keeping severe downward pressure on the stock price.

$OTLC The ongoing Phase 2b/3 trial for Oncotelic’s lead asset, OT-101, is estimated to conclude in mid-2027. Specifically, the pivotal STOP-PC study (NCT06079346), which evaluates the drug in combination with chemotherapy for advanced or metastatic pancreatic cancer, lists an estimated completion date of June 1, 2027. Key Timeline Details: • Current Status: The trial officially began recruiting and enrolling active participants on May 1, 2024. • Scope: The study aims to evaluate approximately 455 patients across multiple treatment groups. • What it means for the stock: Because this timeline stretches over the next several months, Oncotelic must secure enough capital or milestone revenue from its joint-venture partnerships to survive the financial "bridge" leading up to the final data readout. Intermediate interim readouts or data snapshots prior to June 2027 will likely serve as the main catalysts for the stock in the meantime.

$OTLC on radar.- Look Day's Range 0.0241 - 0.0265 52 Week Range 0.0200 - 0.1100 ~~~~~~~~~~~~~~~~ Are you okay any, historical - i don't have script! Wake up. no shadow in the light - Let's move to break out